Kyntra Bio (NASDAQ:KYNB) Rating Lowered to “Strong Sell” at Zacks Research

Kyntra Bio (NASDAQ:KYNB) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday, Zacks reports.

KYNB has been the topic of several other research reports. Oppenheimer started coverage on Kyntra Bio in a research report on Monday, July 6th. They set an “outperform” rating and a $35.00 target price on the stock. Weiss Ratings lowered Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. HC Wainwright restated a “buy” rating and issued a $43.00 price target on shares of Kyntra Bio in a research report on Tuesday, September 1st. Lake Street Capital started coverage on Kyntra Bio in a research report on Thursday, September 17th. They issued a “buy” rating and a $41.00 price target for the company. Finally, Maxim Group assumed coverage on shares of Kyntra Bio in a research note on Tuesday. They set a “buy” rating and a $35.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $36.80.

Kyntra Bio Price Performance

Shares of KYNB stock opened at $5.87 on Monday. Kyntra Bio has a 1 year low of $5.62 and a 1 year high of $11.65. The stock’s 50 day simple moving average is $7.26 and its two-hundred day simple moving average is $7.12. The company has a market cap of $23.77 million, a PE ratio of 0.13 and a beta of 1.05.

Institutional Investors Weigh In On Kyntra Bio

A hedge fund recently bought a new position in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new stake in Kyntra Bio Inc (NASDAQ:KYNB) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio as of its most recent SEC filing. 72.71% of the stock is currently owned by institutional investors.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.